BELBUCA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BELBUCA (BELBUCA).
Partial mu-opioid receptor agonist; produces analgesia by binding to mu-opioid receptors in the CNS, with ceiling effect on respiratory depression.
| Metabolism | Primarily metabolized by CYP3A4 and CYP2C8; minor contribution from CYP2C9 and CYP2C19. |
| Excretion | Primarily renal (70-80% as metabolites, ~15% as unchanged buprenorphine); biliary/fecal excretion accounts for ~10-20%. |
| Half-life | Terminal elimination half-life of buprenorphine is approximately 24-42 hours, allowing for twice-weekly dosing of BELBUCA. |
| Protein binding | Highly protein bound (~96%), primarily to alpha- and beta-globulins, with minimal binding to albumin. |
| Volume of Distribution | Volume of distribution is approximately 2.1 L/kg (range 1.5-3.5 L/kg), indicating extensive tissue distribution. |
| Bioavailability | Absolute bioavailability of buccal buprenorphine is approximately 80-90% compared to intravenous administration. |
| Onset of Action | Onset of analgesia occurs within 30-60 minutes after buccal administration. |
| Duration of Action | Clinical analgesic duration is approximately 12 hours with steady-state achieved within 2-3 days of twice-weekly dosing. |
Apply one buccal film to inner cheek every 12 hours. Initiate at 75 mcg once daily or every 12 hours for opioid-experienced patients; titrate in increments of 75-150 mcg every 4 days. Maximum dose: 900 mcg every 12 hours.
| Dosage form | FILM |
| Renal impairment | For GFR <30 mL/min: reduce starting dose by 50% and titrate cautiously. Not recommended in ESRD. |
| Liver impairment | Child-Pugh Class A: no adjustment. Class B: reduce starting dose by 50%. Class C: avoid use. |
| Pediatric use | Not indicated for pediatric patients under 18 years. |
| Geriatric use | No dose adjustment required based on age alone; monitor for respiratory depression and fall risk, initiate at low end of dosing range (75 mcg every 12 hours). |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BELBUCA (BELBUCA).
| Breastfeeding | Buprenorphine is excreted in breast milk in low concentrations; milk-to-plasma ratio (M/P) approximately 1.0. Limited data show no adverse effects in breastfed infants at maternal doses ≤24 mg/day. Monitor infant for drowsiness, respiratory depression, and feeding difficulties. Use with caution, especially in neonates with underlying respiratory conditions. |
| Teratogenic Risk | Pregnancy Category C. Inadequate studies in pregnant women. Buprenorphine (active ingredient) crosses the placenta. First trimester: Potential risk of neural tube defects based on animal data; human data limited. Second/third trimester: Chronic use may cause neonatal opioid withdrawal syndrome (NOWS); risk of preterm birth, low birth weight. Avoid use unless benefit outweighs risk. |
■ FDA Black Box Warning
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; failure to convert opioid-tolerant patients correctly leads to fatal overdose.
| Serious Effects |
Hypersensitivity to buprenorphine or any component; significant respiratory depression; acute or severe bronchial asthma in unmonitored settings or without resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; patients who are not opioid-tolerant.
| Precautions | Risk of addiction and abuse; life-threatening respiratory depression; neonatal opioid withdrawal syndrome; interactions with CNS depressants; use in patients with adrenal insufficiency; severe hypotension; seizures; use in patients with head injury or increased intracranial pressure; swallowing difficulties with buccal film; withdrawal upon discontinuation; risk of serotonin syndrome with serotonergic drugs; anaphylaxis; use in patients with gastrointestinal obstruction; impaired driving and operating machinery. |
| Food/Dietary |
Loading safety data…
| Fetal Monitoring | Monitor for signs of maternal respiratory depression, sedation, and opioid withdrawal. Assess fetal heart rate and uterine activity during labor. In neonates, monitor for NOWS (e.g., irritability, hypertonia, poor feeding) for at least 48 hours after delivery. Recommend umbilical cord gas analysis if prolonged use. |
| Fertility Effects | Animal studies indicate buprenorphine may impair fertility in males and females at high doses. Human data insufficient; potential for menstrual irregularities and reduced libido due to opioid effects. Effect on spermatogenesis unknown. Discontinuation may reverse effects. |
| Avoid grapefruit and grapefruit juice as they may increase buprenorphine levels. No other specific food interactions. However, patients should avoid consuming hot beverages or foods that might affect buccal absorption until the film is fully dissolved. |
| Clinical Pearls | BELBUCA (buprenorphine) buccal film has a ceiling effect for respiratory depression but not for analgesia. Administer on alternate sides of the buccal mucosa to avoid mucosal irritation. Use the lowest effective dose for the shortest duration. Avoid in patients with severe hepatic impairment (Child-Pugh Class C). Do not abruptly discontinue; taper gradually to avoid withdrawal. |
| Patient Advice | Place the film on the inside of your cheek and hold until dissolved; do not chew or swallow. · Do not eat or drink anything until the film has completely dissolved. · Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines) as they can increase risk of severe side effects. · Store BELBUCA safely out of reach of children and dispose of unused films properly. · Do not drive or operate machinery until you know how BELBUCA affects you. |